These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 2939698)

  • 1. Effects of ketanserin, a selective 5-HT2 serotonergic antagonist, on the secondary recruitment of human platelets in vitro.
    De Clerck F; Xhonneux B
    Agents Actions; 1986 Mar; 17(5-6):515-26. PubMed ID: 2939698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous inhibition of platelet S2-serotonergic receptors during chronic administration of ketanserin in humans.
    De Clerck F; Xhonneux B
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S23-5. PubMed ID: 2412050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The involvement of 5-HT2-receptor sites in the activation of cat platelets.
    De Clerck F; Xhonneux B; Leysen J; Janssen PA
    Thromb Res; 1984 Feb; 33(3):305-21. PubMed ID: 6710435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonist.
    de Clerck F; David JL; Janssen PA
    Agents Actions; 1982 Jul; 12(3):388-97. PubMed ID: 6215842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of ketanserin and mepyramine on platelet aggregation and on the uptake of 5-hydroxytryptamine into platelets.
    Bevan J; Heptinstall S
    Thromb Res; 1983 Jun; 30(5):415-23. PubMed ID: 6612677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of ketanserin on hemostasis in vitro.
    Bergqvist D; Arvidsson S; Haglund U; Hedner U; Lindblad B
    Thromb Res; 1986 Jul; 43(2):237-41. PubMed ID: 2943051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of alpha 2-adrenergic and serotonergic receptor antagonists on cyclic blood flow alterations in stenosed canine coronary arteries.
    Bush LR; Campbell WB; Kern K; Tilton GD; Apprill P; Ashton J; Schmitz J; Buja LM; Willerson JT
    Circ Res; 1984 Nov; 55(5):642-52. PubMed ID: 6488486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5HT2-receptors and serotonin release: their role in human platelet aggregation.
    Cerrito F; Lazzaro MP; Gaudio E; Arminio P; Aloisi G
    Life Sci; 1993; 53(3):209-15. PubMed ID: 8321084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dependence of the antagonism at human platelet 5-HT2 receptors by ketanserin on the reaction pH.
    De Clerck F; Xhonneux B; Tollenaere JP; Janssen PA
    Thromb Res; 1985 Dec; 40(5):581-96. PubMed ID: 2935970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of 5-hydroxytryptamine-potentiated aggregation of human blood platelets by 5-hydroxytryptamine receptor-blocking agents.
    Glusa E; Markwardt F
    Biomed Biochim Acta; 1984; 43(2):215-20. PubMed ID: 6732757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolongation of rat tail bleeding time by ketanserin: mechanisms of action.
    Buczko W; Gambino MC; De Gaetano G
    Eur J Pharmacol; 1984 Aug; 103(3-4):261-8. PubMed ID: 6237923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of 5-HT2-selective agonists on cat platelet aggregation.
    Seggel MR; Qureshi GD; Glennon RA
    Life Sci; 1987 Aug; 41(9):1077-81. PubMed ID: 3613863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potentiation of ADP-induced aggregation in human platelet-rich plasma by 5-hydroxytryptamine and adrenaline.
    Vanags DM; Rodgers SE; Duncan EM; Lloyd JV; Bochner F
    Br J Pharmacol; 1992 Aug; 106(4):917-23. PubMed ID: 1393289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of rat platelet serotonin receptors with tryptamine agonists and the antagonists: ketanserin and SCH 23390.
    Killam AL; Cohen ML
    Thromb Res; 1991 Nov; 64(3):331-40. PubMed ID: 1805448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonergic aspects of the response of human platelets to immune-adjuvant muramyl dipeptide.
    Polanski M; Karnovsky ML
    J Neuroimmunol; 1992 Mar; 37(1-2):149-60. PubMed ID: 1532180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of serotonin-amplified human platelet aggregation by ketanserin, ritanserin, and the ergoline 5HT2 receptor antagonists-LY53857, sergolexole, and LY237733.
    McBride PA; Mann JJ; Nimchinsky E; Cohen ML
    Life Sci; 1990; 47(23):2089-95. PubMed ID: 2125095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet-mediated vascular contractions: inhibition of the serotonergic component by ketanserin.
    De Clerck F; Van Nueten JM
    Thromb Res; 1982 Sep; 27(6):713-27. PubMed ID: 6817452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological profiles of R-96544, the active form of a novel 5-HT2A receptor antagonist R-102444.
    Ogawa T; Sugidachi A; Tanaka N; Fujimoto K; Asai F
    Eur J Pharmacol; 2002 Dec; 457(2-3):107-14. PubMed ID: 12464356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of platelet-derived 5-hydroxytryptamine in thromboxane A2-induced aggregation in cat platelets.
    Ogawa T; Sugidachi A; Asai F; Koike H
    Blood Coagul Fibrinolysis; 1998 Apr; 9(3):233-40. PubMed ID: 9663705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ketanserin prevents platelet aggregation and endotoxin-induced pulmonary vasoconstriction.
    Meuleman TR; Hill DC; Port JD; Stanley TH; Pace NL; Mohammad SF
    Crit Care Med; 1983 Aug; 11(8):606-11. PubMed ID: 6872549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.